文献速递慢性肾脏病水电解质与酸碱

不同磷结合剂对慢性肾脏病维生素D代谢的差异影响

Differential effects of phosphate binders on vitamin D metabolism in chronic kidney disease.
PubMed 文献 · Nephrol Dial Transplant · 2020-01-01

该研究为磷酸盐正常化试验的二次分析,中重度慢性肾脏病患者随机接受安慰剂、碳酸司维拉姆、碳酸镧或醋酸钙治疗9个月。结果显示醋酸钙升高24,25(OH)2D和VMR并降低1,25(OH)2D,碳酸司维拉姆降低24,25(OH)2D3和VMR,碳酸镧无显著影响,提示不同磷结合剂对维生素D代谢有独特效应。

要点

  • 醋酸钙升高24,25(OH)2D和VMR,降低1,25(OH)2D。
  • 碳酸司维拉姆降低24,25(OH)2D3和VMR,对1,25(OH)2D3无影响。
  • 碳酸镧对维生素D代谢物无显著影响。

核心结论

  • 中重度CKD患者使用不同磷结合剂可导致维生素D代谢的独特变化。

研究设计与样本

  • 磷酸盐正常化试验的二次分析,中重度慢性肾脏病患者随机接受安慰剂、碳酸司维拉姆、碳酸镧或醋酸钙治疗9个月。

主要发现

  • 与安慰剂相比,醋酸钙组24,25(OH)2D增加0.6 ng/mL(95% CI 0.2, 1),VMR增加13.5 pg/ng(95% CI 5.5, 21.5),1,25(OH)2D降低5.2 pg/mL(95% CI 1.1, 9.4)。
  • 与安慰剂相比,碳酸司维拉姆组24,25(OH)2D3降低0.5 ng/mL(95% CI -0.9, -0.1),VMR降低11.8 pg/ng(95% CI -20, -3.5)。
  • 碳酸司维拉姆组1,25(OH)2D3变化无显著关联,碳酸镧组任何维生素D代谢物均无显著变化。

临床怎么用

  • 临床选择磷结合剂时需考虑其对维生素D代谢的差异化影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Phosphate binders are commonly used in the treatment of patients with hyperphosphatemia. While phosphate binders are used to lower phosphate, the effects of specific phosphate binder types on vitamin D metabolism are unknown. METHODS: We performed a secondary analysis of the Phosphate Normalization Trial in which patients with moderate to advanced chronic kidney disease were randomized to receive either placebo, sevelamer carbonate, lanthanum carbonate or calcium acetate for 9 months. We evaluated changes in serum concentrations of vitamin D metabolites including 24,25-dihydroxyvitamin D3 [24,25(OH)2D3], 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], the ratio of 24,25(OH)2D3 to 25-hydroxyvitamin D [the vitamin D metabolite ratio (VMR)] and the ratio of serum 1,25(OH)2D to 25-hydroxyvitamin D. RESULTS: Compared with placebo, randomization to the calcium acetate arm was associated with a 0.6 ng/mL (95% CI 0.2, 1) and 13.5 pg/ng (95% CI 5.5, 21.5) increase in 24,25(OH)2D and VMR, respectively, and a 5.2 pg/mL (95% CI 1.1, 9.4) reduction in 1,25(OH)2D. Randomization to sevelamer carbonate was associated with a 0.5 ng/mL (95% CI -0.9, -0.1) and 11.8 pg/ng (95% CI -20, -3.5) reduction in 24,25(OH)2D3 and VMR, respectively. There was no association of the sevelamer arm with the change in 1,25(OH)2D3, and randomization to lanthanum carbonate was not associated with a change in any of the vitamin D metabolites. CONCLUSION: Administration of different phosphate binders to patients with moderate to severe CKD results in unique changes in vitamin D metabolism.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Ginsberg C, Zelnick LR, Block GA, et al. Differential effects of phosphate binders on vitamin D metabolism in chronic kidney disease. Nephrol Dial Transplant. 2020. PMID: 32160298. doi:10.1093/ndt/gfaa010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。